But until recently, we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first FDA-approved drug to slow ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Geographic atrophy (GA) can be visually confusing. People often tell me that one minute they see something, and the next minute they don’t. For example, the word you’re reading might be “she ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related macular degeneration (AMD), a leading cause of blindness. While there are multiple therapies available for ...

today announced positive topline 3-month data from a clinical trial of its K8 implant in patients with geographic atrophy (GA), the most serious form of dry age-related macular degeneration (AMD).

Marci English, vice president, head of biopharma and ophthalmology development, Astellas, said: “Today’s submission comes as good news to people in Japan living with geographic atrophy who have no ...

Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Learn more at www.astellas.com. 3 Colijn JM, Liefers B, Joachim N, et al. Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750.